col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


23 Ergebisse       Seite 1

 [1] 
Wiley: CPT Pharmacometrics & Systems Pharmacology
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Feb―22 Disease-Drug-Drug Interaction of Imatinib in COVID-19 ARDS: A Pooled Population Pharmacokinetic Analysis Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, et al. (+5)
2 [GO] 2024―Nov―20 A theoretical systems chronopharmacology approach for COVID-19: Modeling circadian regulation of lung infection and potential precision therapies Yu-Yao Tseng
3 [GO] 2024―Jun―05 Joint modeling of monocyte HLA-DR expression trajectories predicts 28-day mortality in severe SARS-CoV-2 patients Gaelle Baudemont, Coralie Tardivon, Guillaume Monneret, Martin Cour, Thomas Rimmelé, Lorna Garnier, et al. (+13)
4 [GO] 2024―Mai―24 Development of a SARS-CoV-2 viral dynamic model for patients with COVID-19 based on the amount of viral RNA and viral titer Daichi Yamaguchi, Ryosuke Shimizu, Ryuji Kubota
5 [GO] 2023―Nov―11 Machine Learning-based Integration of Network Features and Chemical Structure of Compounds for SARS-CoV-2 Drug Effect Analysis Julian Späth, Rui-Sheng Wang, Maeve Humphrey, Jan Baumbach, Joseph Loscalzo
6 [GO] 2023―Okt―06 Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals Sébastien Bihorel, Youfang Cao, Akshita Chawla, Ruthie Birger, Brian M. Maas, Wei Gao, et al. (+15)
7 [GO] 2023―Sep―20 Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients Nadège Néant, Guillaume Lingas, Alexandre Gaymard, Drifa Belhadi, Maya Hites, Thérèse Staub, et al. (+13)
8 [GO] 2023―Sep―16 Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans Anna Dari, Philippe Jacqmin, Yuki Iwaki, Martine Neyens, Mathieu Le Gars, Jerald Sadoff, et al. (+3)
9 [GO] 2023―Aug―03 SARS-CoV-2 viral dynamic modelling to inform model selection and timing and efficacy of antiviral therapy Shengyuan Zhang, Akosua A. Agyeman, Christoforos Hadjichrysanthou, Joseph F. Standing
10 [GO] 2023―Jul―04 Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modelling Rob C. van Wijk, Laurynas Mockeliunas, Caryn M. Upton, Jonathan Peter, Andreas H. Diacon, Ulrika S. H. Simonsson
11 [GO] 2022―Apr―12 Quantitative Methods and Modeling to Assess COVID-19-Interrupted in vivo Pharmacokinetic Bioequivalence Studies with Two Reference Batches Yuqing Gong, Kairui Feng, Peijue Zhang, Jieon Lee, Yuzhuo Pan, Zhen Zhang, et al. (+7)
12 [GO] 2022―Mrz―15 PK/PD Modelling Links Accelerated Resolution of COVID-19-Related Clinical Symptoms to SARS-CoV-2 Viral Load Reduction in Patients Following Treatment with Bamlanivimab Alone or Bamlanivimab and Etesevimab Together C. Steven Ernest, Jenny Y. Chien, Dipak R. Patel, Emmanuel Chigutsa
13 [GO] 2021―Nov―18 Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction Asami Sukeishi, Kotaro Itohara, Atsushi Yonezawa, Yuki Sato, Katsuyuki Matsumura, Yoshiki Katada, et al. (+10)
14 [GO] 2021―Okt―06 Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: lessons from the CounterCovid - imatinib - study Imke H. Bartelink, Pierre M. Bet, Nicolas Widmer, Monia Guidi, Erik Duijvelaar, Bram Grob, et al. (+9)
15 [GO] 2021―Jul―31 Application of Quantitative Systems Pharmacology to guide the optimal dosing of COVID-19 vaccines Mario Giorgi, Rajat Desikan, Piet H. Graaf, Andrzej M. Kierzek
16 [GO] 2021―Jul―22 Population Pharmacokinetics of Favipiravir in Patients with COVID-19 Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, et al. (+4)
17 [GO] 2020―Dez―10 A Mechanism-based Pharmacokinetic Model of Remdesivir Leveraging Interspecies Scaling to Simulate COVID-19 Treatment in Humans Patrick O. Hanafin, Brian Jermain, Anthony J. Hickey, Alexander V. Kabanov, Angela D. Kashuba, Timothy P. Sheahan, Gauri G. Rao
18 [GO] 2020―Nov―21 A Prototype QSP Model of the Immune Response to SARS-CoV-2 for Community Development Wei Dai, Rohit Rao, Anna Sher, Nessy Tania, Cynthia J. Musante, Richard Allen
19 [GO] 2020―Nov―18 Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions Meera Varshneya, Itziar Irurzun-Arana, Chiara Campana, Rafael Dariolli, Amy Gutierrez, Taylor K. Pullinger, Eric A. Sobie
20 [GO] 2020―Jul―23 Initiation of Antiviral Treatment in SARS-CoV2: Modeling Viral Dynamics and Drug Properties Daniel Scholes Rosenbloom, Ping Zhao, Vikram Sinha
21 [GO] 2020―Jun―18 Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load Antonio Gonçalves, Julie Bertrand, Ruian Ke, Emmanuelle Comets, Xavier de Lamballerie, Denis Malvy, et al. (+7)
22 [GO] 2020―Jun―08 Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials Jim H. Hughes, Kevin Sweeney, Sima Ahadieh, Daniele Ouellet
23 [GO] 2020―Mai―29 Salvaging CNS Clinical Trials halted due to COVID-19 Hugo Geerts, Piet H. van der Graaf
 [1] 

23 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec